Dextromethorphan‐bupropion shows efficacy in two depression trials
The Brown University Psychopharmacology Update September 1, 2022 DOI: 10.1002/pu.30912 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | Adults with major depressive disorder |
| Topics | Depression |
| Key findings | Dextromethorphan-bupropion was more efficacious than an active comparator and placebo in reducing depressive symptoms, with remission rates separating by week 2. |
Abstract
A medication combining dextromethorphan and bupropion was more efficacious than an active comparator and placebo in reducing depressive symptoms in adults with major depressive disorder, a pair of trials has found. Remission rates with dextromethorphan‐bupropion separated from the comparator and placebo by week 2 of treatment in each study, according to researchers. Results of the Phase 2 trial of the medication were published online May 18 in the American Journal of Psychiatry, and results of the Phase 3 trial were published online May 30 in the Journal of Clinical Psychiatry.
Comparable studies
Other randomized controlled trials on depression, most cited first.